 |
|
1 step closer to green chemistry and improved pharmaceuticals
June 25, 2008Researchers at the University of Copenhagen, Denmark, solve an important piece of the puzzle behind how proteins are shaped
Proteins are the workhorses of our cells. They help to digest our food, are at the core of our immune system, and literally shape our body from top to toe. Proteins also play an important role in biotechnology in the form of enzymes, which are important in the creation of anything from pharmaceuticals to bread, washing powder and much more. Their possibilities are virtually without limit.
To take advantage of their great potential, a detailed understanding of the three-dimensional shape of proteins is necessary. This is normally achieved through a complicated and expensive process in the laboratory. For years, researchers have tried to replace these experiments by computer simulations.
Now, two researchers at the Department of Biology at the University of Copenhagen, Assoc. professor Thomas Hamelryck and PhD-student Wouter Boomsma, have solved an important part of the problem of modeling the three dimensional shape of proteins. After 5 years of research, they have succeeded in developing a mathematical model that incorporates knowledge from physics, probability theory and geometry to describe the structure of proteins. This has given protein researchers a valuable new tool for the improved understanding of the shape and function of proteins.
"Each individual protein has its own unique chemical composition, consisting of 20 different amino acids in various different combinations. There are an endless number of such combinations, each giving rise to its own shape. We have developed a simple mathematical model that captures these different shapes. This means that it will become easier for industry and researchers to use proteins to achieve their goals. For example in the development of green chemistry, where dangerous chemicals are replaced with protein-based products, which are more environment friendly", says Thomas Hamelryck.
Thomas also points to the fact that their computer model can have a great impact on the pharmaceutical industry.
"Proteins and illness are highly related, and most pharmaceuticals are targeted at proteins in our body. As we increase our knowledge of these proteins, the chance of finding more efficient pharmaceuticals for illnesses such as cancer, diabetes and AIDS are greatly enhanced", Thomas continues.
The two researchers at the University of Copenhagen are currently collaborating closely with partners in the biotech industry to explore these possibilities.
University of Copenhagen
Now, two researchers at the Department of Biology at the University of Copenhagen, Assoc. professor Thomas Hamelryck and PhD-student Wouter Boomsma, have solved an important part of the problem of modeling the three dimensional shape of proteins. After 5 years of research, they have succeeded in developing a mathematical model that incorporates knowledge from physics, probability theory and geometry to describe the structure of proteins. This has given protein researchers a valuable new tool for the improved understanding of the shape and function of proteins.
"Each individual protein has its own unique chemical composition, consisting of 20 different amino acids in various different combinations. There are an endless number of such combinations, each giving rise to its own shape. We have developed a simple mathematical model that captures these different shapes. This means that it will become easier for industry and researchers to use proteins to achieve their goals. For example in the development of green chemistry, where dangerous chemicals are replaced with protein-based products, which are more environment friendly", says Thomas Hamelryck.
Thomas also points to the fact that their computer model can have a great impact on the pharmaceutical industry.
"Proteins and illness are highly related, and most pharmaceuticals are targeted at proteins in our body. As we increase our knowledge of these proteins, the chance of finding more efficient pharmaceuticals for illnesses such as cancer, diabetes and AIDS are greatly enhanced", Thomas continues.
The two researchers at the University of Copenhagen are currently collaborating closely with partners in the biotech industry to explore these possibilities.
University of Copenhagen
Pharmaceuticals Current Events and Pharmaceuticals News RSSCancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
Sweet -- sugared polymer a new weapon against allergies and asthma
Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks.
Viagra for women? Drug developed as antidepressant effective in treating low libido
Pooled results from three separate clinical trials of flibanserin, a drug originally created as an antidepressant, show it is effective in treating women with acquired hypoactive sexual desire disorder. These trials were the first ever to test a therapy that works at the level of the brain to enhance libido in women reporting low sexual desire.
Approved lymphoma drug shows promise in early tests against bone cancer
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.
Researchers identify drug candidate for treating spinal muscular atrophy
A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants.
UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin
Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin.
Clinical tests begin on medication to correct Fragile X defect
NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability.
TGen seeks emergency FDA approval of new swine flu test
The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus.
Triple-Combo Drug Shows Promise Against Antiviral-Resistant Swine Flu, UAB Researcher Says
An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.
Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration
Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).
More Pharmaceuticals Current Events and Pharmaceuticals News Articles
 |
Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients by Ray Moynihan (Author), Alan Cassels (Author) Thirty years ago, Henry Gadsden, the head of Merck, one of the world's largest drug companies, told Fortune magazine that he wanted Merck to be more like chewing gum maker Wrigley's. It had long been his dream to make drugs for healthy people so that Merck could "sell to everyone." Gadsden's dream now drives the marketing machinery of the most profitable industry on earth. Drug companies are systematically working to widen the very boundaries that define illness, and the markets for medication grow ever larger. Mild problems are redefined as serious illness and common complaints are labeled as medical conditions requiring drug treatments. Runny noses are now allergic rhinitis, PMS has become a psychiatric disorder, and hyperactive children have ADD. When it comes to conditions like high... |
 |
Saunders Pharmaceutical Word Book 2008 by Ellen Drake CMT FAAMT AHDI-F Educator of the Year Winner (Author), Randy Drake MS (Author) Written by transcriptionists for transcriptionists, this drug reference lets you quickly locate the correct spelling and capitalization of more than 27,000 brand-name and generic drugs. It includes the corresponding uses of those drugs, cross-referencing of brand names to generics, and the usual methods of administration (e.g., capsule, IV, cream). To help you avoid errors, it also contains the indications (reasons for administration) of approved drugs and standard dosages. Over 27,000 brand-name and generic drugs are included, with dosage forms, investigational drug names, chemotherapy protocols, trademarked dosage forms, drug categories/classes, and almost 2,000 medicinal herbs and natural remedies.Pharmaceutical information is organized specifically for the medical... |
 |
Alaven Pharmaceuticals Cystoprotek Soft Gel Capsules, 120-Count Bottle by Alaven Pharmaceutical LLC .caption { font-family: Verdana, Helvetica neue, Arial, serif; font-size: 10px; font-weight: bold; font-style: italic; } ul.indent { list-style: inside disc; text-indent: -15px; } Interstitial Cystitis (IC), also called Painful Bladder Syndrome (PBS), is as bad as it sounds. While there is no known cure for this disorder, CystoProtek can help reduce bladder damage and pain, improving the overall symptoms in patients with IC/PBS. |
 |
Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs by Melody Petersen (Author) An “angrily illuminating” (The New York Times) exposé of Big Pharma’s corrupting influence in America today In the last thirty years, pharmaceutical companies have seized control of American medicine by putting their marketers in charge. They invent diseases in order to sell the pills that "cure" them. They sway doctors by giving them resort vacatopms, gourmet meals, and fistfuls of cash. They advertise prescription drugs at NASCAR races, on subways, and even in churches. Medicines can save lives, but the relentless promotion of these products has come at tremendous cost. Prescription pills taken as directed are estimated to kill one American every five minutes. More Americans are addicted to medications than cocaine. And roads have become less safe as the over-medicated... |
 |
The Truth About the Drug Companies: How They Deceive Us and What to Do About It by Marcia Angell (Author) During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become–and argues for essential, long-overdue... |
 |
Saunders Pharmaceutical Word Book 2010 by Ellen Drake CMT FAAMT AHDI-F Educator of the Year Winner (Author) Written by transcriptionists for transcriptionists, this drug reference lets you quickly locate the correct spelling and capitalization of more than 27,000 brand-name and generic drugs. It includes the corresponding uses of those drugs, cross-referencing of brand names to generics, and the usual methods of administration (e.g., capsule, IV, cream). To help you avoid errors, it also contains the indications of approved drugs and standard dosages. Over 27,000 brand-name and generic drugs are included, with dosage forms, investigational drug names, chemotherapy protocols, trademarked dosage forms, drug categories/classes, and almost 2,000 medicinal herbs and natural remedies.
|
 |
Lipodrene Xtreme by Hi-Tech Pharmaceuticals, Inc. - 90 count by Hi-Tech Pharmaceuticals, Inc. For Advanced Appetite Control and Metabolic Stimulation BENEFITS: Key Benefits of Lipodrene Xtreme Increases the metabolic rate promoting thermogenesis (the burning of stored body fat) Slows the absorption of serotonin which helps in weight management by controlling food cravings and supressing the appetite. Inhibits the absorption of dietary fats by acting as a lipase inhibitor. Lipodrene Xtreme utilizes highly advanced manufacturing technology and unique proprietary ingredients. Hi-Tech believes that this revolutionary formulation will yield results superior to that of ephedra. How Soon Should Lipodrene Xtreme Begin to Work for Me? You should feel the energizing effects in approximately 30 minutes which may last up to six hours. There is no set amount of weight loss however you... |
 |
Kinerase N6-Furfuryladenine Lip Treatment .35 oz (10 g) by Valeant Pharmaceuticals International Non-Comedogenic / Hypoallergenic / For All Skin Types Exclusively for sale in the US Kinerase® Lip Treatment helps visibly smooth and plump lips and surrounding skin while reducing the appearance of fine lines and wrinkles. A high concentration of kinetin and rich emollients deliver essential nutrients for a younger looking smile. valeant.com kinerase.com |
 |
How to Break Into Pharmaceutical Sales: A Headhunter's Strategy by Tom Ruff (Author) Today, more and more candidates are competing for positions in the rewarding field of pharmaceutical sales. With Tom Ruff on your side, you can become one of the breakthrough stories. In his down-to-earth and deeply practical style, the President and CEO of Tom Ruff Company shares the secrets he's gathered over his 18 years of grooming and placing top talent. Widely regarded for his commitment to ethics and excellence, Tom has built a company that is a preferred recruiter for more than 100 of the country's top pharmaceutical and medical device companies, including Abbott Laboratories, Johnson & Johnson and Pfizer. Specializing in the placement of pharmaceutical sales and medical device sales professionals, Tom Ruff Company is headquartered in Manhattan Beach, California, with offices... |
|
Generation RX Starring: Julian Whitaker Directed By: Kevin P. Miller Product Description For decades, scores of doctors, government officials, journalists, and others have extolled the benefits of psychiatric medicines for children. GENERATION RX presents "the rest of the story" and unveils how this era of unprecedented change in Western culture really occurred - and what price has been paid by our society. International award-winning filmmaker Kevin P. Miller (Let Truth Be The Bias, The Promised Land) "delivers a jaw-dropping emotional ride,"* and "weaves a terrifying tale of criminal conspiracy, the mass abandonment of medical ethics, and the routine betrayal of an entire generation."* By employing the expertise of internationally respected professionals from the fields of medicine, ethics, journalism, and academia, GENERATION RX investigates... |
| © 2009 BrightSurf.com |